Literature DB >> 17577864

Ischemic optic neuropathy.

Monica Rodriguez Fontal1, John B Kerrison, Reinaldo Garcia, Veronica Oria.   

Abstract

Ischemic optic neuropathies (IONs) are the most frequent acute optic neuropathy in patients older than 50 years. They are classified according to the location of the ischemic damage into anterior ION and posterior ION. Ischemic optic neuropathies may also be categorized based on the presence or absence of temporal arteritis as an underlying etiology. Anterior ION presents with sudden, painless visual loss developing over hours to days. Examination findings usually include decreased visual acuity, a visual field defect, color vision loss, a relative afferent pupillary defect, and a swollen optic nerve head. Posterior ION occurs in arteritic, nonarteritic, and surgical settings. It is characterized by acute vision loss without initial disc edema but with subsequent optic disc atrophy.

Entities:  

Mesh:

Year:  2007        PMID: 17577864     DOI: 10.1055/s-2007-979686

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  4 in total

1.  Chronic optic disc swelling overlooked in a diabetic patient with a devastating outcome.

Authors:  Tasanee Braithwaite; Gordon T Plant
Journal:  BMJ Case Rep       Date:  2010-03-23

2.  Approach to the patient with acute monocular visual loss.

Authors:  Sashank Prasad; Steven L Galetta
Journal:  Neurol Clin Pract       Date:  2012-03

3.  Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis.

Authors:  Elke Voss; Peter Raab; Corinna Trebst; Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

4.  Association between optic nerve head morphology in open-angle glaucoma and corneal biomechanical parameters measured with Corvis ST.

Authors:  Shuichiro Aoki; Yoshiaki Kiuchi; Kana Tokumo; Yuri Fujino; Masato Matsuura; Hiroshi Murata; Shunsuke Nakakura; Ryo Asaoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-21       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.